SOLUTION / PUBLIC SOURCE RECORD
NordicRWE: Unleashing the power of Nordic health data to bring life-changing therapies to patients faster
- Published 14 February 2025; updated 23 March 2026; estimated reading time 2 minutes. Available in Europe; category Digital health under Health and life science.
- NordicRWE develops solutions and services using Nordic health data for drug development. Its focus is real-world evidence (RWE), derived from real-world data (RWD), to support drug development, healthcare and regulatory processes.
- The article frames the drug-development challenge around personalized medicine and biomarker-driven therapies for smaller patient groups. These create pressure for shorter development timelines and follow-up, use of intermediate endpoints, and conditional approvals, while researchers and decision-makers still need to balance efficacy, safety and cost-effectiveness.
- Nordic countries are described as having universal, publicly funded healthcare systems that collect comprehensive lifelong information on residents. The article calls this “cradle-to-grave” longitudinal data a distinctive resource for life-science research.
- Current RWE application areas: (1) external control arms and emulation studies, comparing new treatments with existing ones, replicating randomized controlled trial findings, and constructing external controls for single-arm trials; (2) drug signal detection, combining hypothesis-free analysis with pharmacoepidemiological validation to support discovery and surveillance; and (3) exploring generative AI and advanced language models on health data for drug-development applications.
- Claimed benefits include access to tailored, high-quality RWD to improve reliability of findings; using RWE to reduce uncertainty and de-risk development decisions; and faster, more efficient therapy development so patients can benefit sooner. The company says it transforms complex RWD into actionable insights and aims to set a global standard for RWE generation.
- The company says its scalable services target global pharmaceutical companies, emerging biotech firms and healthcare providers, with the goal of innovation and measurable improvements in health outcomes. No quantitative market estimate is given on the page.
- Case studies linked: comparative effectiveness of first-line pembrolizumab versus chemotherapy in a Norwegian population cohort with advanced non-small cell lung cancer; comparative effectiveness of atezolizumab, nivolumab and pembrolizumab as second-line treatment for advanced non-small cell lung cancer; and synthetic data as external control arms in scarce single-arm clinical trials.
- Linked to SDG 3, Good health and well-being, through the stated aim of enabling faster and more efficient therapy development.
- Contact: Christian Jonasson, Research Director, cj@nordicrwe.com. Phone number is behind a collapsed reveal control. Company: NORDICRWE AS, Universitetsgata 2, 0164 Oslo, Norway; nordicrwe.com.